MeiraGTx lands $400M debt deal from Oberland, shares up 3.5%
What's the deal? Gene therapy developer MeiraGTx (NASDAQ: MGTX) has secured a $400 million strategic investment from Oberland CapitalDealroom has a profile for this one. Try Dealroom →, structured as non-dilutive debt. Its shares rose 3.5% in premarket trading on the news.
The terms: Oberland will buy up to $400 million of senior secured notes, with the first $250 million tranche funded at closing. The rest becomes available on regulatory milestones and permitted acquisitions.
The financing is interest-only for its full term, with principal due in 2027. It also includes capped milestone and royalty payments tied to future product sales.
Why now? The deal lands as MeiraGTx reports fresh momentum in its pipeline. It recently posted positive three-year data from its Phase 1 AQUAx study of AAV2-hAQP1 for radiation-induced xerostomia, which also won Breakthrough Therapy Designation from the Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →.
The company also reacquired rights to bota-vec, a late-stage therapy for X-linked retinitis pigmentosa with potential for global regulatory filings.
What's the endgame? The capital is meant to strengthen MeiraGTx's balance sheet and advance late-stage programs in Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases. The company points to its end-to-end manufacturing and proprietary riboswitch gene regulation technology as differentiators.
The signal: At $400 million, the deal ranks in the top half of comparable rounds — a sign of investor appetite for late-stage gene therapy backed by clinical data. By raising through debt rather than equity, MeiraGTx funds its pipeline without diluting existing shareholders.
Read more: AInvest
